Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discusses the need to balance personalized targeting with the ethical imperative to protect consumer privacy.
In his video interview with Pharmaceutical Executive, Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab explored the challenges and opportunities in healthcare advertising, particularly in the context of increasing data privacy regulations and the decline of third-party cookies. The discussion highlighted the importance of leveraging real-world data (RWD) to gain valuable insights into patient behavior and preferences. RWD, when combined with advanced analytics and privacy-compliant targeting techniques, enables more effective and targeted advertising campaigns. The conversation also touched on the potential impact of cookie deprecation on the broader advertising industry and the need for advertisers to adapt to a more privacy-centric approach.
I like to say that ethics don't change, but laws do your product and operations organizations really need to have a very strong ethical grounding, which is hopefully, you know, informed by your legal team as well. I usually go back to the principles of privacy by design, which is a set of practices, you know, focused on understanding exactly what is required out of a product and the privacy implications of the components of that product development. It also means learning best practices and staying up to date with what you know is considered to be you know the best class legal guidance and how to operate, especially at a state level.
So, for our part, it's been a very eventful few years in the health data space. We've worked continuously over the last few years to update a lot of things in light of changes to privacy law on a state by state basis, but the best way to stay abreast of that is to also remain up to date with as much information as possible by, say, participating in industry organizations that provide information on that subject. So PurpleLab, for instance, is one of the newest members to the NAI, the healthcare advertising organization that provides a lot of legal information on how you know, state by state, rollouts of different new privacy laws are going into effect, and how best to align our product offerings to be in compliance with those laws.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.